BTK and B-cell chronic lymphocytic leukemia: Targeted inhibitors of the B-cell receptor (BCR) signaling pathway, in particular inhibitors of Bruton tyrosine kinase (BTK), have demonstrated high efficacy across all prognostic subgroups of CLL and thus have largely replaced chemoimmunotherapy [5, 6].